2151477
Project Grant
Overview
Grant Description
Sbir Phase I: Continuous Manufacturing for Nucleic Acid Lipid Nanoparticles to Improve the Supply Chain of Therapeutics and Vaccines (Covid-19) -The Broader Impact /Commercial Potential of This Small Business Innovation Research (Sbir) Phase I Project Addresses the Need for Advanced Manufacturing Technology That Can Produce Future Therapeutics and Vaccines.
Future Clinical Treatments Will Rely on Continuous Manufacturing to Meet Demand, Both with Respect to Volume and Drug Product Personalization. This Project Will Incorporate Continuous Manufacturing Principles and Process Analytical Sensors and Technology. These Processes Will Enable Faster Responses to Global Health Crises, Such as the Covid-19 Pandemic.
This Small Business Innovation Research (Sbir) Phase I Project Will Develop a Compact, End-to-End, Advanced Manufacturing System for Nucleic Acid Lipid Nanoparticles. This New System Will Follow Current Good Manufacturing Practice (Cgmp) and Will Support End-to-End Manufacturing by Connecting to a Nucleic Acid Assembly System and a Fill-Finish System to Produce Injectable-Ready Materials.
One Major Goal of This Research Is to Advance the Understanding of Nanoparticle Drug Delivery to Enable Manufacturing Injectable Ready Materials on Demand and On-Site.
This Award Reflects Nsf's Statutory Mission and Has Been Deemed Worthy of Support Through Evaluation Using the Foundation's Intellectual Merit and Broader Impacts Review Criteria.
Future Clinical Treatments Will Rely on Continuous Manufacturing to Meet Demand, Both with Respect to Volume and Drug Product Personalization. This Project Will Incorporate Continuous Manufacturing Principles and Process Analytical Sensors and Technology. These Processes Will Enable Faster Responses to Global Health Crises, Such as the Covid-19 Pandemic.
This Small Business Innovation Research (Sbir) Phase I Project Will Develop a Compact, End-to-End, Advanced Manufacturing System for Nucleic Acid Lipid Nanoparticles. This New System Will Follow Current Good Manufacturing Practice (Cgmp) and Will Support End-to-End Manufacturing by Connecting to a Nucleic Acid Assembly System and a Fill-Finish System to Produce Injectable-Ready Materials.
One Major Goal of This Research Is to Advance the Understanding of Nanoparticle Drug Delivery to Enable Manufacturing Injectable Ready Materials on Demand and On-Site.
This Award Reflects Nsf's Statutory Mission and Has Been Deemed Worthy of Support Through Evaluation Using the Foundation's Intellectual Merit and Broader Impacts Review Criteria.
Awardee
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Storrs Mansfield,
Connecticut
06269-4213
United States
Geographic Scope
Single Zip Code
Related Opportunity
None
Diant Pharma was awarded
Project Grant 2151477
worth $256,000
from Directorate for Technology, Innovation and Partnerships in February 2022 with work to be completed primarily in Storrs Mansfield Connecticut United States.
The grant
has a duration of 9 months and
was awarded through assistance program 47.041 Engineering.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I:Continuous Manufacturing for Nucleic Acid Lipid Nanoparticles to Improve the Supply Chain of Therapeutics and Vaccines (COVID-19)
Abstract
The broader impact /commercial potential of this Small Business Innovation Research (SBIR) Phase I project addresses the need for advanced manufacturing technology that can produce future therapeutics and vaccines. Future clinical treatments will rely on continuous manufacturing to meet demand, both with respect to volume and drug product personalization. This project will incorporate continuous manufacturing principles and process analytical sensors and technology. These processes will enable faster responses to global health crises, such as the COVID-19 pandemic.This Small Business Innovation Research (SBIR) Phase I project will develop a compact, end-to-end, advanced manufacturing system for nucleic acid lipid nanoparticles.This new system will follow current Good Manufacturing Practice (cGMP) and will support end-to-end manufacturing by connecting to a nucleic acid assembly system and a fill-finish system to produce injectable-ready materials. One major goal of this research is to advance the understanding of nanoparticle drug delivery to enable manufacturing injectable ready materials on demand and on-site.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
PT
Solicitation Number
NSF 21-562
Status
(Complete)
Last Modified 2/18/22
Period of Performance
2/15/22
Start Date
11/30/22
End Date
Funding Split
$256.0K
Federal Obligation
$0.0
Non-Federal Obligation
$256.0K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2151477
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
490707 DIVISION OF INDUSTRIAL INNOVATION
Funding Office
490707 DIVISION OF INDUSTRIAL INNOVATION
Awardee UEI
KSC4E53LAX37
Awardee CAGE
8CYJ5
Performance District
02
Senators
Richard Blumenthal
Christopher Murphy
Christopher Murphy
Representative
Joe Courtney
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Research and Related Activities, National Science Foundation (049-0100) | General science and basic research | Grants, subsidies, and contributions (41.0) | $256,000 | 100% |
Modified: 2/18/22